Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents
Throughout the last decades, newly developed chemotherapeutic agents and immunotherapies that target signaling pathways have provided patients with better prognoses, improved their quality of life and increased survival rates, thus converting cancer to a stable chronic disease. However, non-anthracy...
Main Authors: | Alexandros Briasoulis, Angeliki Chasouraki, Alexandros Sianis, Nikolaos Panagiotou, Christos Kourek, Argyrios Ntalianis, Ioannis Paraskevaidis |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-02-01
|
Series: | Journal of Cardiovascular Development and Disease |
Subjects: | |
Online Access: | https://www.mdpi.com/2308-3425/9/3/66 |
Similar Items
-
Anthracycline-Induced Cardiotoxicity
by: Radomír Hrdina, et al.
Published: (2000-01-01) -
Practical Approaches to Build and Sustain a Cardio-Oncology Clinic
by: Angeliki Chasouraki, et al.
Published: (2022-05-01) -
High Density Lipoprotein and Its Precursor Protein Apolipoprotein A1 as Potential Therapeutics to Prevent Anthracycline Associated Cardiotoxicity
by: George E. G. Kluck, et al.
Published: (2020-04-01) -
Cardioprotective Strategies from Cardiotoxicity in Cancer Patients: A Comprehensive Review
by: Christos Kourek, et al.
Published: (2022-08-01) -
Cardioprotection From Cardiotoxicity
by: Guilherme H. Oliveira, MD, MBA
Published: (2019-09-01)